Brazikumab

DRUG2 trials

Sponsors

AstraZeneca

Conditions

Healthy ParticipantsIBDUlcerative Colitis

Phase 1

Study to Evaluate the Pharmacokinetics (Movement of Drugs Within the Body), Safety and Tolerability of Brazikumab in Healthy Chinese and White Participants

CompletedNCT05033431

AstraZenecaHealthy Participants

Start: 2021-10-11End: 2022-10-12Updated: 2022-10-27

Phase 2

Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis

TerminatedNCT03616821

AstraZenecaIBD, Ulcerative Colitis

Start: 2018-08-07End: 2023-10-23Updated: 2026-06-23

Related Papers

DOP077 EndoUC: an AI-assisted endoscopic Ulcerative Colitis activity grading application for deployment in clinical trials

Journal of Crohn s and Colitis2025-01-012 citations